High IDO expression in macrophages and endothelial cells in TME are related to anti-PD-1 non-responsiveness in metastatic renal cell carcinoma and sarcomas patients undergoing anti-PD-1 treatment with pembrolizumab or nivolumab antibodies (223, 224). The gene discussed is PDCD1; the disease is sarcoma.